Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDUA | P35475 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | AGL | P35573 | 2/20 | 0.44 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 1/20 | 0.44 |
| ▸ | MGAM | O43451 | 5/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.42 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269870 | 1.00 | IDUA (0.47) | IDUAGLAGAAAGLGBA2 | |
| SCHEMBL2436662 | 1.00 | IDUA (0.47) | IDUAGLAGAAAGLGBA2 | |
| SCHEMBL8878544 | 1.00 | IDUA (0.47) | IDUAGLAGAAAGLGBA2 | |
| SCHEMBL19575262 | 1.00 | IDUA (0.47) | IDUAGLAGAAAGLGBA2 | |
| SCHEMBL4606758 | 0.93 | MAN2B1 (0.45) | IDUAGLAGAAAGLGBA2 | |
| SCHEMBL4605168 | 0.93 | MAN2B1 (0.45) | IDUAGLAGAAAGLGBA2 | |
| SCHEMBL15031115 | 0.78 | GLA (0.41) | GLAGAAAGLGBA2GBA1 | |
| SCHEMBL13367189 | 0.78 | GLA (0.41) | GLAGAAAGLGBA2GBA1 | |
| SCHEMBL16134370 | 0.78 | FUCA1 (0.43) | GLAGAAAGLGBA2GBA1 | |
| SCHEMBL13339121 | 0.78 | GLA (0.41) | GLAGAAAGLGBA2GBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | SUMMIT CORPORATION PLC (GB) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | IDUA 9/4885GLA 13/4885GAA 1/4885 |
| US-20110195929-A1 | COMPOUNDS FOR THE TREATMENT OF FLAVIVIRAL INFECTIONS | GPI, GALE, HAVCR2 | IDUA 52/4885GLA 496/4885GAA 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.